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Abstract
Background: Right extended liver resection is frequently required to achieve tumor-free margins. Portal venous
embolization (PVE) of the prospective resected hepatic segments for conditioning segments II/III does not always
induce adequate hypertrophy in segments II and III (future liver remnant volume (FLRV)) for extended right-
resection. Here, we present the technique of in situ split dissection along segments II/III plus portal disruption to
segments IV-VIII (ISLT) as a salvage procedure to overcome inadequate gain of FLRV after PVE.
Methods: In eight patients, FLRV was further pre-conditioned following failed PVE prior to hepatectomy (ISLT-
group). We compared FLRV changes in the ISLT group with patients receiving extended right hepatectomy
following sufficient PVE (PVEres-group). Survival of the ISLT-group was compared to PVEres patients and PVE
patients with insufficient FLRV gain or tumor progress who did not receive further surgery (PVEnores-group).
Results: Patient characteristics and surgical outcome were comparable in both groups. The mean FLRV-to-body-
weight ratio in the ISLT group was smaller than in the PVEres-group pre- and post-PVE. One intraoperative mortality
due to a coronary infarction was observed for an ISLT patient. ISLT was successfully completed in the remaining
seven ISLT patients. Liver function and 2-year survival of ~ 50% was comparable to patients with extended right
hepatectomy after efficient PVE. Patients who received a PVE but who were not subsequently resected (PVEnores)
demonstrated no survival beyond 4 months.
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Conclusion: Despite extended embolization of segments I and IV-VIII, ISLT should be considered if hypertrophy was
not adequate. Liver function and overall survival after ISLT was comparable to patients with trisectionectomy after
efficient PVE.
Keywords: ALPPS, Liver resection, In situ split, Future liver remnant, Liver hypertrophy
Background
To date, surgical hepatic resection is the only curative treat-
ment for patients with primary or secondary liver malig-
nancies that can achieve complete tumor removal with
tumor-free resection margins. However, the extend of liver
resection remains a challenging factor that is limited by the
size of the future liver remnant volume (FLRV). In the past,
extended liver resection even with a sufficient FLRV has
been feared due to the increased risk of postoperative liver
failure [1–5]. In the past years, much progress has been
made to induce hypertrophy in the FLRV before major
hepatectomy [6]. Portal vein embolization (PVE) represents
a well-established standard treatment to increase the FLRV
by up to 40% [7–10]. However, it usually takes up to 6–8
weeks after PVE to achieve an adequate liver volume for ex-
tended liver surgery; this interval can be as long as 150 days
[6, 10]. Moreover, it was reported that PVE has a failure
rate of 20–30% as a result of tumor progression or inad-
equate hypertrophy [8, 11–14]. In cases where PVE does
not induce timely hypertrophy, the risk of tumor progres-
sion increases while awaiting sufficient FLRV to assure a
safe extended liver resection [12, 13, 15].
Recently, a new technique for hepatic resection called
in situ split dissection along segments II and III plus
portal disruption to hepatic segments IV to VIII (ISLT)
also called ALPPS (Associating Liver Partition and Portal
Vein Ligation for Staged Hepatectomy) has been intro-
duced to induce an accelerated response of the FLRV
within a reasonable period of time [16–22]. To date,
only a few reports with small patient numbers exist that
describe various ISLT procedures as a rescue strategy to
overcome failed “classical” portal occlusion measures;
these include interventional embolization and open sur-
gical portal ligation concepts. The various ISLT tech-
niques were developed to provide an alternative
approach to induce adequate FLRV growth while pre-
serving the perspective of a potential curative surgical
strategy [4, 5, 21, 23–26]. Here, we present a large
single-center experience with ISLT as a salvage proced-
ure for inefficient PVE of segments I/IV-VIII as a last
measure to gain adequate FLRV.
Methods
Patients
Between January 2009 and January 2019, medical re-
cords of 48 consecutive patients scheduled for extended
right hepatectomy (resection of hepatic segments I + IV
to VIII) for primary or secondary liver malignancies
were reviewed from the prospective clinical tumor regis-
try, which is maintained by our oncological liver surgery
program at the Department of General, Visceral, Thorax
and Pediatric Surgery, University Hospital Duesseldorf,
Germany. All of these patients were initially judged to
be unresectable due to an insufficient FLRV (cumulative
volume of segments II and III). Out of this cohort, 23
patients were scheduled for immediate ISLT (Fig. 1).
A further 25 patients underwent PVE followed by re-
evaluation of the FLRV before extended liver resection.
Out of those 25 patients, extended right hepatectomy
was performed in 12 patients after efficient PVE treat-
ment and were categorized as PVEres-group (Fig. 1).
PVE treatment was insufficient in 13 patients. Eight of
these patients were scheduled for a salvage ISLT proced-
ure to achieve an adequate FLRV, and were analyzed in
this retrospective study as ISLT-group (Fig. 1). Five out
of the 13 failed PVE patients were not eligible for further
surgery due to insufficient FLRV gain or decisive tumor
progression and were included as a separate group for
analyses (PVEnores-group).
We compared survival time following the date that
irresectability was determined after PVE in the
PVEnores-group with survival after the last scheduled
hepatic surgical intervention in the other two patient co-
horts in this study. Further patient characteristics and
surgical outcome were compared between the groups.
All patients with locally advanced liver malignancies
were discussed and reviewed by a multidisciplinary
tumor board including gastroenterologists, surgeons,
radiation oncologists, pathologists and radiologists. This
study was approved by the local institutional review
board (Heinrich Heine University, Duesseldorf,
Germany; study-no.: 2018–258-KFogU). All procedures
performed in this study were in accordance with the eth-
ical standards in the 1964 Declaration of Helsinki and its
later amendments. Informed consent was waived be-
cause no data regarding the cases were disclosed.
The following parameters were obtained: patients
characteristics including gender, age, ASA (American
Society of Anesthesiologists) score, BMI (body mass
index) and diabetes, oncological characteristics including
tumor type, TNM stage, grading, R-status and neoadju-
vant chemotherapy as well as surgical characteristics
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including hospital stay, morbidity and postoperative 90-
day mortality rates, survival, postoperative liver function
and radiological data with volume gain of FLRV. Postop-
erative complications were classified I-IV according to
the Clavien-Dindo classification [27].
Hepatic volumetric assessments and portal vein
embolization
Patients underwent routine staging by using preoperative
helical computed tomography (CT) scanning of the
chest, abdomen, and pelvis. Initial total liver volumes
(TLV) that excluded tumor volume (TV) and the FLRV
were estimated at time of indication for hepatic resec-
tion by CT. Measurements were performed manually
with respect to the hepatic segmentation based on the
distribution of the portal pedicles and the location of the
hepatic veins (Couinaud terminology) as previously de-
scribed [21, 28]. From week 2 post PVE, differential ab-
solute, relative and daily gains of the FLRV post-PVE
were calculated in 2–3 weeks intervals to measure the
change in hepatic volume: before PVE, after PVE and be-
fore resection. Patients after ISLT received CT volume-
try every week.
Two methods for FLRV evaluation extrapolated from
liver transplantation literature were applied to evaluate
the sufficiency of the FLRV prior hepatic resection.
Those are a) the ratio of FLRV to total liver volume and
b) the ratio of FLRV to body weight (FLRVbw). In our
study, we utilized method b) for determing the threshold
of liver volume for resectability to exclude a
phenomenon possible in method a) which is comparing
parts of normal liver parenchyma to others compro-
mised by biliary or vascular obstruction, by portal vein
embolization or disturbance in measurement due to
tumor volume as also discussed elsewere [29]. Extrapo-
lating from living-donor liver transplantation, we hy-
pothesized that FLRVbw more accurately assesses the
functional limit of hepatectomy. For the FLRVbw, a ratio
of of 0.4 to 0.5 was determined to be sufficient [29, 30].
For extensive hepatic resection surgery as performed in
this study, we set a rather conservative threshold of 0.5
for volumetric resectability in non-cirrotic patients as
proposed also by others [30].
For PVE, a transileocolic portal venous approach was
used. After visualization of the portal venous tree, his-
toacryl or polyvinyl alcohol particles were applied to oc-
clude portovenous branches to liver segments I/IV-VIII
as previously described [21]. After the hypertrophy
period, an extended right hepatectomy was performed.
Surgical technique
The surgical technique for ISLT was performed as previ-
ously described [21]. In brief, for the ISLT procedure in
stage 1, the right portal vein was divided, whereas the
right hepatic artery and right bile duct were identified
and marked with a vessel loop for later transection dur-
ing stage 2. After complete liver mobilization and tran-
section of all retrohepatic veins, the liver parenchyma
between segments II/III and I/IV-VIII was transected by
using a cavitron ultrasonic surgical aspirator (CUSA®,
Valleylab, Boulder,Colorado/USA) [21]. In stage 2, the
Fig. 1 Flow chart of patient collective
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right hepatic artery and right bile duct were transected
and the resected liver was removed.
Posthepatectomy liver failure
Posthepatectomy liver failure (PHLV) was defined as the
impaired ability of the liver to maintain its synthetic, ex-
cretory, and detoxifying functions, which was character-
ized by an increased international normalized ratio
(INR) and concomitant hyperbilirubinemia according to
the normal range of cut-off labels of our local laboratory
on or after postoperative day (POD) 5 [31]. When INR
or bilirubin were already increased preoperatively, PHLF
was defined by increased values on or after POD 5 com-
pared to the values of the previous day as previously de-
scribed [31].
Statistics
All data were retrospectively collected and transferred
into a database. Statistical analysis and graphing were
performed using MS Excel and JMP 14.1 from SAS In-
stitute Inc., Cary, USA. All results are expressed as
mean ± standard deviation. Statistical significance was
determined by Student’s t test and Chi-Square test. Sur-
vival curves significance was defined as *p < 0.05. **p <
0.01. The Kaplan-Meier method was used to estimate
survival curves.
Results
Patient characteristics
Median age within PVEres and ISLT groups overall was
67 years and was comparable among these two cohorts
(PVEres range: 44–81; ISLT range: 49–81 years, p = 0.92)
(Table 1). In the ISLT group was 62.5% male [5] and
37.5% female [3] patients. The PVEres group included
seven male (58.3%) and five (41.7%) female patients (p =
0.85). ASA score (p = 0.12), BMI (p = 0.73) and diabetes
(p = 0.49) were equally distributed between the study
groups.
Surgical characteristics and outcome
There was no significant difference between the PVEres
and the ISLT groups regarding mean hospital stay (36.3
days +/− 28.2 vs. 30 days +/− 28.9; p = 0.63; Table 1).
Complication were classified according to the Dindo-
Clavien classification [27]. There were no significant dif-
ferences in minor or major postoperative complications
between the ISLT and the PVEres group (p = 0.49). Four
patients (33%) in the PVEres group and one patient
(13%) in the ISLT group had an uneventful postoperative
course without any minor or major complication. Minor
complications (grade I-IIIa) related to resection occurred
in two patients (17%) and one patient (13%) respectively.
This included two wound infections and two patients
with cholangitis. Major complications (grade IIIb-IVb)
occured in six patients in each group (50% versus 75%
respectively) (Table 1). Three PVEres-patients (25%) and
two patients after ISLT (25%) had postoperative bile
leaks. Posthepatectomy liver failure with increased INR
or hyperbilirubinemia on or after postoperative day 5
occurred in three PVEres patients (25%) and one ISLT
patient (13%) respectively. Two patients (17%) in the
PVEres group and one patient (13%) in the ISLT group
developed temporary renal failure. One failed hepaticoje-
junostomy, which needed revision surgery, and one
acute respiratory distress syndrome occurred in the ISLT
group. In the PVEres group, one small-bowel perforation
with intestinal fistula and one case of postoperative
bleeding occurred.
The 90-day mortality rate following extended right re-
section (stage 2 in the ISLT-group) was 14.3% in the
ISLT-group (n = 1/7; data not shown) and 25% in the
PVEres-group (3/12). Overall 90-day mortality subse-
quent to the last scheduled resection-concept surgery
(stage 1 or 2) was 25% in both groups (PVEres: 3/12;
Table 1 Patient and surgical characteristics comparing ISLT
(n = 8) and PVEres (n = 12) group
PVEres ISLT p-value
n = 12 n = 8
Patient characteristics
Age years (mean + SD) 67.5 + 11.2 67 + 9.8 0.92
Gender n (%) 0.85
Male 7 (58.3) 5 (62.5)
Female 5 (41.7) 3 (37.5)
ASA score n (%) 0.12
2 6 (75) 2 (33.3)
3 2 (25) 4 (66.7)
BMI (mean + SD) 26.5 + 3.7 27.1 + 4.2 0.73
Diabetes n (%) 0.49
Yes 3 (25) 1 (12.5)
No 9 (75) 7 (87.5)
Surgical characteristics and early outcome
Hospital stay (d)
(median + SD)
36.3 + 28.2 30.0 + 28.9 0.63
Morbidity (Dindo/Clavien)
n (%)
0.49
no complication 4 (33.3) 1 (12.5)
I-IIIa 2 (16.7) 1 12.5)
IIIb-IVb 6 (50) 6 (75)
Postop 90-day mortality n (%) 3 (25) 2 (25) 1
ASA American Society of Anesthesiologists, BMI body mass index, CCC
cholangiocellular carcinoma, CRLM colorectal liver metastasis, d days, HCC
hepatocellular carcinoma, ISLT patients with in situ split transection along
segments II and III plus portal ligation to hepatic segments IV to VIII, RCLM
renal cell carcinoma liver metastasis, NET neuroendocrine tumor, N node, M
metastases, PVEres extended right hepatectomy promptly following sufficient
PVE, SD standard deviation, T tumor
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ISLT: 2/8; p = 1; Table 2). For the ISLT group, one pa-
tient died during the split procedure due to a fatal cor-
onary infarction and one patient developed a myocardial
infarction on day 7 following resection-completion sur-
gery with lethal outcome. In the PVEres group, two
patients died from septic multi organ failure. One pa-
tient died as a result of postoperative liver failure. How-
ever, there were no significant differences among groups
regarding major complications (p = 0.49) or regarding
the 90-day mortality (Table 1).
Oncological characteristics
Diagnosis for extended right hepatectomy showed
various tumor types with no statistical difference in our
two groups (Table 2). Likewise, neither TNM classifica-
tion nor tumor grading caused a significant difference
between the study groups. 25% of patients (PVEres: 3;
ISLT: 2) received neoadjuvant radiochemotherapy (p =
1). Local R0 (margin-free) resection could be achieved in
92% (PVEres) and 88% (ISLT) of the resected patients
(p = 0.34). The mean number of liver lesions was 2.4 for
the PVEres group compared to 4 in the ISLT group with
no statistical difference. The maximum tumor diameter
ranged 31–115 mm in the ISLT group compared to 14–
180 mm in the PVEres group with no statistical differ-
ence (Table 2).
Growth of FLRV following PVE +/− ISLT
The mean initial FLRV prior to PVE was 276 ml + 69 in
the PVEres group versus 346 ml + 86 in the ISLT group
(Fig. 2a). After PVE treatment, the PVEres patients dem-
onstrated a significant mean increase of 428 ml + 140
compared to ISLT patients with 333ml + 86. However,
seven of the patients who showed an insufficient hyper-
trophy of the FLRV and who then received a rescue split
procedure revealed a significant 2-fold mean increase in
liver growth (from 333ml + 86 to 621 ml + 388) before
second-stage surgery (Fig. 2a). This effect was resembled
in the % to body weight ratio for FLRV (Fig. 2b). The
mean FLRV to body weight ratio (FLRVbw) in the ISLT
group was smaller before PVE (0.35 +/− 0.09%) and post
PVE (0.42 +/− 0.08%) compared to the PVEres-group
(0.49 +/− 0.17% and 0.67 +/− 0.05%) (Fig. 2b). For exten-
sive hepatic resection surgery as performed in this study,
we adopted a rather conservative threshold of 0.5 for
volumetric resectability in non-cirrotic patients as previ-
ously described [30]. Post PVE or post split, we accepted
a FLRVbw of 0.4 if an increase in FLRV of at least 20%
as a sign of adequate regenerative response was
achieved. In seven patients, ISLT was successfully com-
pleted with a mean FLRVbw of 0.81 +/− 0.09% receiving
a completion of the extended right hepatectomy.
PVEnores patients (n = 5) demonstrated a slower
growth of the FLRV compared to PVEres patients (n =
12) (Suppl. Fig. 1A and B). Four of these patients (pre-
ISLT-era of our hepatic resection program) demon-
strated inadequate liver growth with an insufficient
FLRV. One patient, however, showed sufficient FLRV
hypertrophy, but experienced significant tumor progress
Table 2 Oncological characteristics comparing ISLT (n = 8) and
PVEres (n = 12) group
PVEres ISLT p-value
n = 12 n = 8
Oncological characteristics
Tumor Type n (%) 0.7
CRLM 3 (25) 2 (25)
RCCLM 0 1 (12.5)
HCC 3 (25) 2 (25)
CCC 5 (41.7) 3 (37.5)
NET 1 (8.3) 0
TNM stage n (%)
T-stage 0.88
1 2 (16.7) 2 (28.6)
2 2 (16.7) 1 (14.3)
3 7 (58.3) 3 (42.9)
4 1 (8.3) 1 (14.3)
N-stage n (%) 0.31
0 7 (58.3) 2 (25)
1 4 (33.3) 3 (37.5)
2 0 1 (12.5)
Nx 1 (8.3) 2 (25)
M-stage n (%) 0.21
0 7 (58.3) 2 (25)
1 5 (41.7) 5 (62.5)
Mx 0 1 (12.5)
Grading n (%) 0.2
G2 8 (66.7) 8 (100)
G3 3 (25) 0
Gx 1 (8.3) 0
Neoadjuvant chemotherapy n (%) 1
Yes 3 (25) 2 (25)
No 9 (75) 6 (75)
R-status n (%) 0.34
R0 11 (91.7) 7 (87.5)
R1 1 (8.3) 0
Rx 0 1 (12.5)
Number of lesions (mean + SD) 2 + 1.9 4 + 4.6 0.36
Maximum tumor diameter
(mean + SD)
80.5 + 47.1 66.3 + 27.7 0.51
d days, ISLT patients with in situ split transection along segments II and III plus
portal disruption to hepatic segments IV to VIII, PVEres extended right
hepatectomy promptly following sufficient PVE, SD standard deviation
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with peritoneal carcinomatosis as detected during surgi-
cal exploration.
Survival analysis and liver function
With a median follow up of 84.2 months (9.2–132.5
months) overall survival subsequent to the last
scheduled hepatic resection-concept surgery was
comparable between the ISLT (n = 8) and the PVEres
group (n = 12) with a 2-year survival of 50 and 45.5%
respectively (p = 0.8) (Fig. 3a). This is despite conser-
vative data presentation and interpretation with inclu-
sion of the one stage 1 intraoperative mortality in the
ISLT group latter due to fatal cardiac infarction. Sur-
vival analyses revealed a strong survival benefit for
the ISLT group when compared to the PVEnores
Fig. 2 a. ISLT (PVE + in situ split + resection) patients demonstrated a significant increase in FLRV post split. b. Increase in FLRV to bodyweight
ratio post split for ISLT group. The dotted line indicates the critical FLR to bodyweight ratio of 0.5. BW: body weight. FLRV: future liver remnant
volume. ml: milliliter. *p < 0.05; ***p < 0.01
Fig. 3 Survival analysis: a. Kaplan Meier Survial curve demonstrates similar survival in ISLT (PVE + in situ split + resection) and PVEres (PVE +
resection) groups. b. ISLT patients show significant longer survival compared to PVEnores (PVE only without resection) patients as demonstrated
by Kaplan Meier analysis
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group. PVEnores patients demonstrated a significantly
shorter survival with no patient alive beyond 4
months (p = 0.03) (Fig. 3b).
Looking at liver function in the clinical course prior
PVE, post PVE, and one and two weeks post liver resec-
tion, our data did not reveal any statistical differences
after ISLT and completion extended right hepatectomy
(Fig. 4). Both groups demonstrated a non-significant 5-
fold increase in bilirubin as a sign for transient liver in-
sufficiency (prior PVE: PVEres 1 mg/dl + 1.3, ISLT 0.5
mg/dl + 0.3; 2 weeks post op: PVEres 5.8 mg/dl + 5.7,
ISLT 4mg/dl + 4.8) (Fig. 4a). Aspartate aminotransfer-
ase levels were slightly increased one week post resec-
tion in the PVEres group, but returned almost to
normal within two weeks for both groups (Fig. 4b).
Both INR and creatinine comparably increased after
liver resection one week and two weeks post-op for the
two groups (Fig. 4c & d).
Discussion
This study represents the largest single-center experi-
ence with ISLT performed as salvage procedure subse-
quent to inefficient one-step PVE of all hepatic segments
(I/IV-VIII) except II and III. We have previously
presented the novel in situ split liver procedure in three
patients subsequent to inefficient PVE [21]. In this
follow-up study, we demonstrated a comparable out-
come after extended right liver resection subsequent to
PVE plus ISLT and immediately subsequent to sufficient
PVE respectively.
Commensurability of the two groups was demon-
strated by comparable patient characteristics including
age distribution, co-morbidity and oncological profiles.
Our patient population was more heterogeneous from
oncologic indications such as CCC, HCC, NET and
CRLM; this is in contrast to a recent single center ex-
perience on 5 patients solely with colorectal liver
Fig. 4 Mean (s.d.) a. bilirubin, b. glutamate-oxalacetate-transaminase (GOT) and glutamate-pyruvate-transaminase (GPT), c. international
normalized ratio (INR) and d. creatinine levels pre PVE, pre operation, 1 week and 2 weeks after resection for ISLT (PVE + in situ split + resection)
and PVEres (PVE + resection) patients. I.U.: international units
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metastases (CRLM), who were subjected to rescue ISLT
following PVE [4]. This study deviated from our investi-
gation in that only segments V to VIII were embolized.
These patients underwent atypical CRLM liver resec-
tions in segments I-III in the course of the ISLT surgery
(stage 1) and segments IV to VIII in stage 2 surgery,
leaving segment I in place. This was also performed in
all but one of the 17 patients in the largest series of res-
cue ISLT subsequent to failed PVE to date reported on a
collective derived from an ISLT (ALPPS) database based
on 12 hospitals [5]. In this study, PVE was mainly lim-
ited to the right portal branch; segment IV was only ad-
dressed in one case. Another recent study performed by
Ulmer et al demonstrates the largest single-center ex-
perience of 9 patients with rescue ALPPS following in-
sufficient hypertrophy after PVE [26]. However, PVE on
segment I was not performed in this study either. In our
study, we present eight patients with intention to treat
subsequent to failed PVE of segments I and IV to VIII.
Out of this group, first stage ISLT was followed by sec-
ond stage extended right hepatectomy (segments I + IV
to VIII) in seven cases. Because we have routinely oc-
cluded all portal branches to the to-be-resected seg-
ments including segment I, which is unique to all
previous mentioned studies, we have applied the full po-
tential of PVE with limited residual perfusion of the
right side. However, how much influence these portal-
venous shunts have on liver growth, needs to be further
investigated.
The ISLT procedure is a relatively novel technique,
which has evoked a hot debate in the last few years be-
cause it is known to be paralleled by high morbidity and
mortality rates, especially in patients with primary liver
tumors or cirrhosis patients [6, 22, 32–34]. Previous re-
ports suggest that careful patient selection for ISLT is
necessary to reduce the mortality [6, 35, 36]. The advan-
tage of ISLT strategies is clearly seen in the high prolif-
erative stimulus that induces hypertrophy of the FLRV
at a rate that is unmatched by PVE [17, 37–39]. An in-
adequate increase in the FLRV after PVE is a challenging
and limiting problem which represents an exclusion cri-
teria for extended hepatic resection [2, 3, 34, 40, 41].
The development of left to right portal venous shunt-
ing in spite of PVE occlusion has been shown to nega-
tively correlate with FLRV hypertrophy [42, 43]. The
improved gain in FLRV subsequent to the ISLT proce-
dures may be a result of the improved isolation of the
non-future liver remnant from portal blood supply by
transecting the plain for collateral formation along the
border of segment IV and segments II /III. Further, spar-
ing segment IV in the course of PVE concepts seems to
be associated with compromised levels of FLRV gain
[44], which is supported by our observation that PVE
with inclusion of segment IV is more effective for
increasing the FLRV than open right portal ligation [10].
Although segment IV perfusion via segmental portal
branches is not influenced by the ISLT procedure itself,
a two-sided isolation of hepatic segment IV - that is the
PVE-occluded portal supply from central and collaterals
along falciform ligament on the other side - might
maximize the FLRV gain after the ISLT. Moreover, it
seems advisable to address segment IV during PVE in
order to achieve the maximum PVE-effect and to reduce
the chance of a failed PVE.
The mean 90-day mortality after extended right re-
section (stage 2) following ISLT (stage 1) of 14.3%
(n = 1/7) is in the scope of that reported by others of
up to 16% [35]. Lower rates such as 8.8% have been
reported in series with patients exclusively treated for
CRLM [4]. The ALPPS registry did not reveal any
morbidity or mortality rates after rescue ISLT [5].
However, our patient collective demonstrated an aver-
age age of 67 years; this might be relevant for the in-
terpretation of the herein reported mortality because
patient age beyond 60 years is associated with an in-
creased risk for morbidity and mortality due to im-
paired regenerative potential [45].
For cases of ISLT as a rescue measure, we and others
[4, 5, 23, 26] have demonstrated the preserved capacity
to gain the FLRV even with previously failed portal oc-
clusion concepts. Even on a small number of patients,
we could demonstrate for the first time long-term out-
come on patients after ISLT in this single center ana-
lysis. We revealed a comparable overall survival after
resection in the ISLT group compared with patients
resected subsequent to sufficient PVE. Without the op-
tion of ISLT, those patients would have been categorized
as inoperable. Our survival data demonstrate a survival
benefit of ISLT individuals over patients in our program
who did not reach eligibility for resective surgery due to
inadequate FLRV. All non-resected patients died within
4 months.
The amount of liver growth does not necessarily re-
flect the liver function, especially in patients with
chronic liver diseases. However, markers of hepatic dam-
age, metabolism and syntheses were comparable in the
course following extended right resection in insufficient
PVE plus ISLT patients and adequate PVE alone individ-
uals respectively. These data suggest that liver function
follows volume subsequent to ISLT as a salvage strategy
to pre-condition the FLRV after failed PVE.
Obviously, this study has some limitations. Even
though we present a large single-center experience of
eight patients in this selected patient group, it remains a
small heterogenous collective with patients with different
tumor entities especially in the ISLT and non-resection
groups. However, it was conducted with standardized
and uniform PVE and surgical strategies, which was not
Lehwald-Tywuschik et al. BMC Surgery           (2020) 20:63 Page 8 of 10
the case in other multicenter studies that have reported
on that topic so far [4, 5, 23]. Furthermore, due to the
heterogeneity concerning oncological background
leading to resective surgery it is very difficult to compare
patients, although the resection groups here were com-
parable among each other to that respect. To overcome
some of this limitations, multicentered prospective trials
with harmonized interventional and surgical concepts
are required to reach an acceptable level of comparabil-
ity and to draw the right conclusions for clinical
practice. Facing a rather infrequent phenomenon of a
therapeutic concept, implemented in a limited number
of liver resection programs, such a study will be challen-
ging, but vital to accomplish. This kind of study may
provide criteria and the decision guidance for the opti-
mal timespan between PVE and making the choice
whether to proceed with ISLT or to perform a single-
stage extended hepatic resection.
Conclusion
In summary, our results showed similar liver function
and comparable overall survival for patients who under-
went a rescue ISLT after inadequate PVE compared to
those with immediate extended right hepatectomy sub-
sequent to initially sufficient PVE. We believe that ISLT
could be applied earlier after failed PVE because the
complication rate is not unfavorable and we could dem-
onstrate a clear survival benefit. Consequently, patients
should be re-evaluated 6–8 weeks after PVE, and in cases
of inadequate FLRV growth, ISLT can be safely consid-
ered as an intermediate step to achieve operability.
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